Abstract
The main focus of this report is the MR spectroscopy of the changes in the concentration of fluorine labeled photosensitizer that occur following the IP administration. This process is studied by 19F in vivo MR methodology in a murine tumor model. The animal model used in these studies was mice bearing radiation induced fibrosarcoma (RIF) tumor on the foot dorsum. The mice were injected with a solution of ∼ 100 micro-moles of the fluorinated photosensitizer and the 19F MR examination of the photosensitizer in the tumor or the muscle was performed. The pharmacokinetic (PK) profile for each labeled compound was generated using the 19F MR data at various time points post photosensitizer administration. The pharmacokinetic parameters were analyzed and the relationship of these results to photodynamic therapy is discussed. 19F MR methods clearly demonstrate utility in measuring the pharmacokinetic profiles and provide a new approach in the evaluation of appropriate photosensitizers for use in preclinical mammalian systems.
Keywords: 19F MR, RIF tumor, pharmacokinetics, fluorine labeled photosensitizers, photodynamic therapy (PDT), photofrin
Current Drug Discovery Technologies
Title: In vivo 19F MR Studies of Fluorine Labeled Photosensitizers in a Murine Tumor Model
Volume: 4 Issue: 2
Author(s): Subbaraya Ramaprasad, Elzbieta Ripp, Joseph Missert and Ravindra K. Pandey
Affiliation:
Keywords: 19F MR, RIF tumor, pharmacokinetics, fluorine labeled photosensitizers, photodynamic therapy (PDT), photofrin
Abstract: The main focus of this report is the MR spectroscopy of the changes in the concentration of fluorine labeled photosensitizer that occur following the IP administration. This process is studied by 19F in vivo MR methodology in a murine tumor model. The animal model used in these studies was mice bearing radiation induced fibrosarcoma (RIF) tumor on the foot dorsum. The mice were injected with a solution of ∼ 100 micro-moles of the fluorinated photosensitizer and the 19F MR examination of the photosensitizer in the tumor or the muscle was performed. The pharmacokinetic (PK) profile for each labeled compound was generated using the 19F MR data at various time points post photosensitizer administration. The pharmacokinetic parameters were analyzed and the relationship of these results to photodynamic therapy is discussed. 19F MR methods clearly demonstrate utility in measuring the pharmacokinetic profiles and provide a new approach in the evaluation of appropriate photosensitizers for use in preclinical mammalian systems.
Export Options
About this article
Cite this article as:
Subbaraya Ramaprasad , Elzbieta Ripp , Joseph Missert and Ravindra K. Pandey , In vivo 19F MR Studies of Fluorine Labeled Photosensitizers in a Murine Tumor Model, Current Drug Discovery Technologies 2007; 4 (2) . https://dx.doi.org/10.2174/157016307781483423
DOI https://dx.doi.org/10.2174/157016307781483423 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry Three-Decade Failure to the Eradication of Refractory <i>Helicobacter pylori</i> Infection and Recent Efforts to Eradicate the Infection
Current Pharmaceutical Biotechnology Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design Trends in Enzyme Inhibition and Activation in Drug Design - Part II
Current Topics in Medicinal Chemistry Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Pomegranate as a Possible Treatment in Reducing Risk of Developing Wound Healing, Obesity, Neurodegenerative Disorders, and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target
Current Topics in Medicinal Chemistry Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Current Medicinal Chemistry Clinical Proteomics in Cancer Research – Promises and Limitations of Current Two-Dimensional Gel Electrophoresis
Current Medicinal Chemistry The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry A Curcumin Analog, GO-Y078, Effectively Inhibits Angiogenesis through Actin Disorganization
Anti-Cancer Agents in Medicinal Chemistry Folate Tethered Gd2O3 Nanoparticles Exhibit Photoactive Antimicrobial Effects and pH Responsive Delivery of 5-fluorouracil into MCF-7 Cells
Drug Delivery Letters Design, Synthesis and Biological Evaluation of Palladium (II) Complexes with 1-(substituted benzyl) azetidine-3,3-dicarboxylates as Leaving Group
Medicinal Chemistry Design and Optimization of Domperidone Fast Dissolving Tablet Using Central Composite Design
Current Drug Delivery Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Invertebrate FMRFamide Related Peptides
Protein & Peptide Letters Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of Camptothecin Conjugated with NSAIDs as Novel Dual-actin Antitumor Agents
Letters in Drug Design & Discovery